What caused ALVAL.PA stock to surge today?

The rise to €1.10 and **15.79%** gain was driven by heavy trading volume (**2,680,090**), movement above the 50-day average, and investor focus on Valbiotis' clinical pipeline and upcoming earnings on 02 Mar 2026.

What is Meyka AI's rating for ALVAL.PA stock?

Meyka AI rates ALVAL.PA **58.32/100** (Grade **C+**, Suggestion: **HOLD**). This score combines benchmark, sector, financial growth, metrics, forecasts, and analyst consensus; it is informational, not financial advice.

What price targets and forecast does Meyka AI give for ALVAL.PA stock?

Meyka AI's forecast model projects a quarterly price of **€0.83** and a monthly price of **€0.47**. Scenario targets: bull **€1.50**, base **€1.20**, bear **€0.80**. Forecasts are model-based and not guarantees.

What are the main risks for ALVAL.PA stock?

Primary risks include negative EPS (**-0.70**), high price-to-sales (**52.63**), potential dilution from financing, and binary clinical outcomes. Liquidity can amplify moves around news events.

EU Stocks

ALVAL.PA rises 15.79% to €1.10 on 30 Jan 2026 (EURONEXT): watch volume

ByDanny Kontos January 31, 2026January 31, 2026

ALVAL.PA stock led some of today’s top gainers on EURONEXT, rising 15.79% to €1.10 on 30 Jan 2026 as volume spiked to 2,680,090 shares. The move follows a run above the 50-day average price of €0.71 and a push toward the year high of €1.46. Traders priced in pipeline progress and short-covering into the close, making ALVAL.PA one of the most active biotech tickers in Europe today.